These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 8926739

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2.
    Fraser AD, Worth D.
    Forensic Sci Int; 2003 Apr 23; 133(1-2):26-31. PubMed ID: 12742686
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.
    Schlienz NJ, Cone EJ, Herrmann ES, Lembeck NA, Mitchell JM, Bigelow GE, Flegel R, LoDico CP, Hayes ED, Vandrey R.
    J Anal Toxicol; 2018 May 01; 42(4):232-247. PubMed ID: 29300962
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A comparison of Roche Kinetic Interaction of Microparticles in Solution (KIMS) assay for cannabinoids and GC-MS analysis for 11-nor-9-carboxy-delta9-tetrahydrocannabinol.
    Lyons TP, Okano CK, Kuhnle JA, Bruins MR, Darwin WD, Moolchan ET, Huestis MA.
    J Anal Toxicol; 2001 Oct 01; 25(7):559-64. PubMed ID: 11599600
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV.
    Fraser AD, Worth D.
    Forensic Sci Int; 2004 Jul 16; 143(2-3):147-52. PubMed ID: 15240035
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle.
    Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA, Waga J, Kurtz L, Bronsgeest M, Cone EJ.
    J Anal Toxicol; 2005 Oct 16; 29(7):607-15. PubMed ID: 16419389
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Passive cannabis smoke exposure and oral fluid testing.
    Niedbala S, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ.
    J Anal Toxicol; 2004 Oct 16; 28(7):546-52. PubMed ID: 15516313
    [Abstract] [Full Text] [Related]

  • 17. Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration.
    Smith ML, Shimomura ET, Summers J, Paul BD, Nichols D, Shippee R, Jenkins AJ, Darwin WD, Cone EJ.
    J Anal Toxicol; 2000 Oct 16; 24(7):522-9. PubMed ID: 11043654
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lowering the federally mandated cannabinoid immunoassay cutoff increases true-positive results.
    Huestis MA, Mitchell JM, Cone EJ.
    Clin Chem; 1994 May 16; 40(5):729-33. PubMed ID: 8174244
    [Abstract] [Full Text] [Related]

  • 20. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.
    Johansson E, Halldin MM.
    J Anal Toxicol; 1989 May 16; 13(4):218-23. PubMed ID: 2550702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.